Human Microbiome Market by Product (Probiotics, Prebiotics, Medical Foods, Supplements, and Others), by Application (Therapeutics and Diagnostics) and by Disease Type (Obesity, Diabetes, Autoimmune Disorder, Metabolic & Gastrointestinal Disorders, Cancer, and Other Diseases): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2024

Description

The report covers forecast and analysis for the human microbiome market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the human microbiome market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the human microbiome market on a global level.

In order to give the users of this report a comprehensive view of the human microbiome market, we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service type launch, agreements, partnerships, collaborations & joint ventures, research & development, service type and regional expansion of major participants involved in the market.

The study provides a decisive view of the human microbiome market by segmenting it into the product, application, disease type, and region. All the segments have been analyzed based on present and the future trends and the market is estimated from 2018 to 2024. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further categorization into major countries including the U.S., the UK, Germany, France, China, Japan, India, Brazil, etc. This segmentation includes demand for human microbiome market based on all segments in all the regions and countries.

The key players in the global human microbiome market are AOBiome LLC, Second Genome, Seres Therapeutics, Osel, Inc., Metabiomics Corp., uBiome, Inc., Rebiotix, Inc., Enterome, Vedanta Biosciences, Synthetic Biologics, Inc., and Biosciences

This report segments the global human microbiome market as follows:

Global Human Microbiome Market: Product Segment Analysis

• Probiotics
• Prebiotics
• Medical Foods
• Supplements
• Others

Global Human Microbiome Market: Application Segment Analysis

• Therapeutics
• Diagnostics

Global Human Microbiome Market: Disease Type Segment Analysis

• Obesity
• Diabetes
• Autoimmune Disorder
• Metabolic & Gastrointestinal Disorder
• Cancer
• Others

Global Human Microbiome Market: Regional Segment Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

Table Of Content

• Chapter 1. Introduction
  • 1.1. Report description and scope
  • 1.2. Research scope
  • 1.3. Research methodology
    • 1.3.1. Market research process
    • 1.3.2. Market research methodology
• Chapter 2. Executive Summary
  • 2.1. Global human microbiome market, 2015 - 2024 (USD Million)
  • 2.2. Global human microbiome market: Snapshot
• Chapter 3. Human Microbiome Market - Market Dynamics
  • 3.1. Introduction
  • 3.2. Market drivers
    • 3.2.1. Global human microbiome market drivers: Impact analysis
    • 3.2.2. Early diagnosis of diseases using human microbiome
    • 3.2.3. Increase in demand for personalized medicines
  • 3.3. Market restraints
    • 3.3.1. Global human microbiome market restraints: Impact analysis
    • 3.3.2. Lack of expertise & detailed research
  • 3.4. Opportunities
    • 3.4.1. Development of new drugs using human microbiome
  • 3.5. Porter's five forces analysis
    • 3.5.1. Bargaining power of suppliers
    • 3.5.2. Bargaining power of buyers
    • 3.5.3. Threat from new entrants
    • 3.5.4. Threat from new substitutes
    • 3.5.5. Degree of competition
  • 3.6. Market attractiveness analysis
    • 3.6.1. Market attractiveness analysis, by product segment
    • 3.6.2. Market attractiveness analysis, by application segment
    • 3.6.3. Market attractiveness analysis, by disease type segment
    • 3.6.4. Market attractiveness analysis, by regional segment
• Chapter 4. Global Human Microbiome Market - Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global human microbiome market: company market share, 2017
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New material launch
    • 4.2.3. Agreements, partnerships, collaborations and joint ventures
    • 4.2.4. Research and development and regional expansion
• Chapter 5. Global Human Microbiome Market -Product Segment Analysis
  • 5.1. Global human microbiome market: Product overview
    • 5.1.1. Global human microbiome market revenue share, by product, 2017 and 2024
  • 5.2. Probiotics
    • 5.2.1. Global human microbiome market for probiotics, 2015 - 2024 (USD Million)
  • 5.3. Prebiotics
    • 5.3.1. Global human microbiome market for prebiotics, 2015 - 2024 (USD Million)
  • 5.4. Medical Foods
    • 5.4.1. Global human microbiome market for medical foods, 2015 - 2024 (USD Million)
  • 5.5. Supplements
    • 5.5.1. Global human microbiome market for supplements, 2015 - 2024 (USD Million)
  • 5.6. Others
    • 5.6.1. Global human microbiome market for others, 2015 - 2024 (USD Million)
• Chapter 6. Global Human Microbiome Market -Application Segment Analysis
  • 6.1. Global human microbiome market: Application overview
    • 6.1.1. Global human microbiome market revenue share, by application, 2017 and 2024
  • 6.2. Therapeutics
    • 6.2.1. Global human microbiome market for therapeutics, 2015 - 2024 (USD Million)
  • 6.3. Diagnostics
    • 6.3.1. Global human microbiome market for diagnostics, 2015 - 2024 (USD Million)
• Chapter 7. Global Human Microbiome Market - Disease Type Segment Analysis
  • 7.1. Global human microbiome market: disease type overview
    • 7.1.1. Global human microbiome market revenue share, by disease type, 2017 and 2024
  • 7.2. Obesity
    • 7.2.1. Global human microbiome market for obesity, 2015 - 2024 (USD Million)
  • 7.3. Diabetes
    • 7.3.1. Global human microbiome market for diabetes, 2015 - 2024 (USD Million)
  • 7.4. Autoimmune Disorder
    • 7.4.1. Global human microbiome market for autoimmune disorder, 2015 - 2024 (USD Million)
  • 7.5. Metabolic Disorder
    • 7.5.1. Global human microbiome market for metabolic disorder, 2015 - 2024 (USD Million)
  • 7.6. Cancer
    • 7.6.1. Global human microbiome market for cancer, 2015 - 2024 (USD Million)
  • 7.7. Other disease type
    • 7.7.1. Global human microbiome market for other disease type, 2015 - 2024 (USD Million)
• Chapter 8. Global Human Microbiome Market - Regional Segment Analysis
  • 8.1. Global human microbiome market: Regional overview
    • 8.1.1. Global human microbiome market revenue share, by region, 2017 and 2024
  • 8.2. North America
    • 8.2.1. North America human microbiome market, 2015 - 2024 (USD Million)
    • 8.2.2. North America human microbiome market revenue, by product, 2015 - 2024 (USD Million)
    • 8.2.3. North America human microbiome market revenue, by application, 2015 - 2024 (USD Million)
    • 8.2.4. North America human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.2.5. The U.S.
      • 8.2.5.1. The U.S. human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.2.5.2. The U.S. human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.2.5.3. The U.S. human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.2.6. Canada
      • 8.2.6.1. Canada human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.2.6.2. Canada human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.2.6.3. Canada human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe human microbiome market, 2015 - 2024 (USD Million)
    • 8.3.2. Europe human microbiome market revenue, by product, 2015 - 2024 (USD Million)
    • 8.3.3. Europe human microbiome market revenue, by application, 2015 - 2024 (USD Million)
    • 8.3.4. Europe human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.3.5. UK
      • 8.3.5.1. UK human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.3.5.2. UK human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.3.5.3. UK human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.3.6. Germany
      • 8.3.6.1. Germany human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.3.6.2. Germany human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.3.6.3. Germany human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.3.7. France
      • 8.3.7.1. France human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.3.7.2. France human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.3.7.3. France human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.3.8. Rest of Europe
      • 8.3.8.1. Rest of Europe human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.3.8.2. Rest of Europe human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.3.8.3. Rest of Europe human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific human microbiome market, 2015 - 2024 (USD Million)
    • 8.4.2. Asia Pacific human microbiome market revenue, by product, 2015 - 2024 (USD Million)
    • 8.4.3. Asia Pacific human microbiome market revenue, by application, 2015 - 2024 (USD Million)
    • 8.4.4. Asia Pacific human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.4.5. China
      • 8.4.5.1. China human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.4.5.2. China human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.4.5.3. China human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.4.6. Japan
      • 8.4.6.1. Japan human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.4.6.2. Japan human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.4.6.3. Japan human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.4.7. India
      • 8.4.7.1. India human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.4.7.2. India human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.4.7.3. India human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.4.8. Rest of Asia Pacific
      • 8.4.8.1. Rest of Asia Pacific human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.4.8.2. Rest of Asia Pacific human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.4.8.3. Rest of Asia Pacific human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America human microbiome market, 2015 - 2024 (USD Million)
    • 8.5.2. Latin America human microbiome market revenue, by product, 2015 - 2024 (USD Million)
    • 8.5.3. Latin America human microbiome market revenue, by application, 2015 - 2024 (USD Million)
    • 8.5.4. Latin America human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.5.5. Brazil
      • 8.5.5.1. Brazil human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.5.5.2. Brazil human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.5.5.3. Brazil human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
    • 8.5.6. Rest of Latin America
      • 8.5.6.1. Rest of Latin America human microbiome market revenue, by product, 2015 - 2024 (USD Million)
      • 8.5.6.2. Rest of Latin America human microbiome market revenue, by application, 2015 - 2024 (USD Million)
      • 8.5.6.3. Rest of Latin America human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
  • 8.6. The Middle East and Africa
    • 8.6.1. The Middle East and Africa human microbiome market, 2015 - 2024 (USD Million)
    • 8.6.2. The Middle East and Africa human microbiome market revenue, by product, 2015 - 2024 (USD Million)
    • 8.6.3. The Middle East and Africa human microbiome market revenue, by application, 2015 - 2024 (USD Million)
    • 8.6.4. The Middle East and Africa human microbiome market revenue, by disease type, 2015 - 2024 (USD Million)
• Chapter 9. Company Profiles
  • 9.1. AOBiome LLC
    • 9.1.1. Overview
    • 9.1.2. Financials
    • 9.1.3. Product Portfolio
    • 9.1.4. Business Strategy
    • 9.1.5. Recent Developments
  • 9.2. Osel, Inc.
    • 9.2.1. Overview
    • 9.2.2. Financials
    • 9.2.3. Product Portfolio
    • 9.2.4. Business Strategy
    • 9.2.5. Recent Developments
  • 9.3. Seres Therapeutics
    • 9.3.1. Overview
    • 9.3.2. Financials
    • 9.3.3. Product Portfolio
    • 9.3.4. Business Strategy
    • 9.3.5. Recent Developments
  • 9.4. Second Genome
    • 9.4.1. Overview
    • 9.4.2. Financials
    • 9.4.3. Product Portfolio
    • 9.4.4. Business Strategy
    • 9.4.5. Recent Developments
  • 9.5. uBiome, Inc.
    • 9.5.1. Overview
    • 9.5.2. Financials
    • 9.5.3. Product Portfolio
    • 9.5.4. Business Strategy
    • 9.5.5. Recent Developments
  • 9.6. Metabiomics Corp.
    • 9.6.1. Overview
    • 9.6.2. Financials
    • 9.6.3. Product Portfolio
    • 9.6.4. Business Strategy
    • 9.6.5. Recent Developments
  • 9.7. Rebiotix, Inc.
    • 9.7.1. Overview
    • 9.7.2. Financials
    • 9.7.3. Product Portfolio
    • 9.7.4. Business Strategy
    • 9.7.5. Recent Developments
  • 9.8. Vedanta Biosciences
    • 9.8.1. Overview
    • 9.8.2. Financials
    • 9.8.3. Product Portfolio
    • 9.8.4. Business Strategy
    • 9.8.5. Recent Developments
  • 9.9. Enterome Biosciences
    • 9.9.1. Overview
    • 9.9.2. Financials
    • 9.9.3. Product Portfolio
    • 9.9.4. Business Strategy
    • 9.9.5. Recent Developments
  • 9.10. Synthetic Biologics, Inc.
    • 9.10.1. Overview
    • 9.10.2. Financials
    • 9.10.3. Product Portfolio
    • 9.10.4. Business Strategy
    • 9.10.5. Recent Developments 

Methodology

Free Analysis

The human microbiome is the full array of the microbiota (microorganisms) that reside in or on the human body. Specifically, these are the collection of the genomes of microbes that contribute to the metagenome, i.e., a genetic portrait of humans.

According to the CDC, in 2015-16, over 93.3 million adults in the U.S. were obese. The human microbiome helps the body to improve the digestion system due to which the metabolic activities increases. These help the obese people to control the weight & initiate their weight loss. The rapid awareness about the use of human microbiome to treat diseases like diabetes, autoimmune disorders, obesity, etc. is fueling the growth of the global human microbiome market. Also, increased research in this field, use of human microbiome for drug development, and need of early diagnosis of various diseases are expected to drive the growth of the global human microbiome market.

Human microbiome market is segmented on the basis of product, application, and disease type. Based on the product, the human microbiome market is further segmented into prebiotics, probiotics, medical foods, supplements, & others. Probiotics segment is anticipated to dominate the product segment of the human microbiome market. The growth in awareness about the beneficial properties of prebiotics is expected to fuel the growth of the prebiotics segment. Based on application, the human microbiome market is further segmented into therapeutics application & diagnostics application. The increase in research yielding new applications and usage of the human microbiome is expected to fuel the growth of the therapeutic market. The disease type segment is further segmented into obesity, diabetes, an autoimmune disorder, metabolic & gastrointestinal disorders, cancer & other diseases. Metabolic & gastrointestinal diseases segment is expected to dominate the market in the forecast period due to rise in awareness about the use of human microbiome in the treatment of metabolic & gastrointestinal diseases.

North America is anticipated to dominate the human microbiome market in the forecast period due to the increase in the number of ongoing clinical trials, increase in the prevalence of a disease such as diabetes & cancer, and early adoption of recently developed technologies. The Asia Pacific is expected to show the highest growth rate in the forecast period due to rapid awareness about the benefits of the human microbiome & rapid development & innovations in the research. Also, increase in a number of initiatives that aims to optimize the method for studying the effect of the gut microbiome on human health through the various protocols and procedures is anticipated to fuel the growth of Asia Pacific market.

The main players involved in the global human microbiome market are AOBiome LLC, Second Genome, Seres Therapeutics, Osel, Inc., Metabiomics Corp., uBiome, Inc., Rebiotix, Inc., Enterome Biosciences, Vedanta Biosciences, and Synthetic Biologics, Inc. The major companies are focusing on providing the microbiomes which are useful for the treatment of different diseases & disorders. For instance, in April 2018, AOBiome Therapeutics, initiated a clinical trial for Ammonia-Oxidizing Bacteria to treat an Episodic Migraine.